Journal of Vaccines & Vaccination

Baylor Scott & White Health, Texas, USA

Biography

Thomas Kutty is currently working as a Professor in the Department of Vaccines. His research interests includes Vaccines. He has successfully completed his Administrative responsibilities. Thomas Kutty has authored of many research articles/books related to Vaccines

Publications

• Research Article   
  Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial
  Author(s): Alben Sigamani*, Mathu Ruthra, Sudhishma, Samarth Shetty, Madhavi, Anup Chugani, Hana Chen-Walden, David Platt and Thomas Kutty
  
  Importance: Novel SARS-CoV-2 virus has infected nearly 100 million people across the world and is highly contagious. There is a need for a novel mechanism to block viral entry and stop its replication. Background: Spike protein N Terminal Domain (NTD) of the novel SARS-CoV-2 is essential for viral entry and replication in human cell. Thus the S1 NTD of human coronavirus family, which is similar to a galectin binding site-human galactose binding lectins, is a potential novel target for early treatment in COVID-19. Objectives: To study the feasibility of performing a definitive trial of using galectin antagonist–Prolectin-M as treatment for mild, symptomatic, rRT-PCR positive, COVID-19. Main outcomes and measures: Cycle threshold (Ct) value is number of cycles needed to express.. View more»
  

  DOI: 10.35248/2157-7560.21.S10.003

  Abstract HTML PDF